Chemed Corporation $CHE Holdings Decreased by California Public Employees Retirement System

California Public Employees Retirement System cut its position in shares of Chemed Corporation (NYSE:CHE) by 15.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,037 shares of the company’s stock after selling 10,414 shares during the quarter. California Public Employees Retirement System owned 0.40% of Chemed worth $28,260,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Creekmur Asset Management LLC bought a new position in Chemed in the second quarter worth about $28,000. SVB Wealth LLC bought a new position in shares of Chemed during the first quarter valued at approximately $30,000. WPG Advisers LLC acquired a new stake in shares of Chemed during the 1st quarter worth approximately $32,000. Parkside Financial Bank & Trust lifted its holdings in shares of Chemed by 86.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock worth $46,000 after purchasing an additional 44 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Performance

Chemed stock opened at $425.41 on Thursday. The firm has a market cap of $6.02 billion, a price-to-earnings ratio of 22.50, a price-to-earnings-growth ratio of 2.35 and a beta of 0.46. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The firm’s 50 day moving average price is $436.27 and its two-hundred day moving average price is $465.94.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million during the quarter, compared to analysts’ expectations of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts predict that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Monday, November 17th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, November 17th. Chemed’s payout ratio is 12.69%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CHE shares. Bank of America cut their target price on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and lifted their price objective for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th. Royal Bank Of Canada decreased their target price on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Finally, Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Chemed currently has a consensus rating of “Moderate Buy” and an average target price of $574.25.

Insider Buying and Selling at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the transaction, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.29% of the stock is owned by corporate insiders.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.